US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today announced that it has resolved all patent litigation related to lawsuits resulting from Abbreviated New Drug Applications (ANDAs) brought by companies seeking approval to market a generic version of Ingrezza (valbenazine) prior to the expiration of applicable Neurocrine patents.
As part of the resolution of these lawsuits, four companies have the right to sell generic versions of Ingrezza in the USA beginning March 1, 2038, or earlier under certain customary circumstances.
"These settlements reinforce our belief in the strength of the Ingrezza intellectual property estate and provide clarity regarding Ingrezza exclusivity. As an innovation-driven biopharmaceutical company, we will continue to develop treatments for under-addressed diseases and rely on a robust patent system to protect that investment in innovation," said Darin Lippoldt, chief legal officer of Neurocrine Biosciences.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze